Kala Pharmaceuticals Inc./$KALA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kala Pharmaceuticals Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Ticker
$KALA
Sector
Primary listing
Employees
6
Headquarters
Website
KALA Metrics
BasicAdvanced
$101m
-
-$3.31
-1.99
-
Price and volume
Market cap
$101m
Beta
-1.99
52-week high
$20.60
52-week low
$0.10
Average daily volume
3.4m
Financial strength
Current ratio
3.805
Quick ratio
3.03
Interest coverage (TTM)
-12.95%
Profitability
EBITDA (TTM)
-42.092
Management effectiveness
Return on assets (TTM)
-81.59%
Return on equity (TTM)
-279.18%
Valuation
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.028
Free cash flow yield (TTM)
-3,604.90%
Free cash flow per share (TTM)
-3.928
Growth
Earnings per share change (TTM)
-67.36%
3-year earnings per share growth (CAGR)
-51.75%
10-year earnings per share growth (CAGR)
-41.82%
KALA News
AllArticlesVideos
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
Benzinga·1 month ago
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Newsfile Corp·2 months ago
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Newsfile Corp·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kala Pharmaceuticals Inc. stock?
Kala Pharmaceuticals Inc. (KALA) has a market cap of $101M as of May 04, 2026.
What is the P/E ratio for Kala Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Kala Pharmaceuticals Inc. (KALA) stock is 0 as of May 04, 2026.
Does Kala Pharmaceuticals Inc. stock pay dividends?
No, Kala Pharmaceuticals Inc. (KALA) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Kala Pharmaceuticals Inc. dividend payment date?
Kala Pharmaceuticals Inc. (KALA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kala Pharmaceuticals Inc.?
Kala Pharmaceuticals Inc. (KALA) has a beta rating of -1.99. This means that it has an inverse relation to market volatility.